{"id":"W2337227118","doi":"10.1016/s1556-0864(16)30250-7","title":"140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Erlotinib; Adverse effect; Randomized controlled trial; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002232321,0.002706594,0.003600666,0.0006911746,0.0004610678,0.001889402,0.001405963,0.00268328,0.01144896],"category_scores_gemma":[0.001792907,0.00105205,0.003337553,0.000586521,0.00191872,0.001913708,0.0007462256,0.005851533,0.002449686],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001330432,"about_ca_system_score_gemma":0.001879181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0016377,"about_ca_topic_score_gemma":0.004981986,"domain_scores_codex":[0.9992085,0.0003928074,0.00003675566,0.000130485,0.00004950999,0.0001818536],"domain_scores_gemma":[0.9992747,0.0001609053,0.0001210637,0.00004781599,0.00004563508,0.0003499761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9547919,0.006371066,0.0007763042,0.0010429,0.001533189,0.00005373035,0.0001144735,0.0008529641,0.005449973,0.0003387916,0.00300294,0.02567188],"study_design_scores_gemma":[0.9656516,0.03203218,0.0007859605,0.00002123663,0.0002599134,0.00003575757,0.00002438552,0.0002515021,0.0001997694,0.0001523652,0.0005700069,0.00001529468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9718773,0.006622325,0.001417842,0.002558133,0.001057581,0.005849334,0.004383222,0.0006577859,0.005576512],"genre_scores_gemma":[0.9687395,0.00435084,0.002984602,0.003464218,0.0006410629,0.00580138,0.006311997,0.0001508974,0.007555544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01144896,"threshold_uncertainty_score":0.03830057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03421572737096714,"score_gpt":0.4650041278192836,"score_spread":0.4307884004483165,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}